Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Artery | 6 | 2025 | 442 | 1.320 |
Why?
|
| Hypertension, Pulmonary | 6 | 2025 | 452 | 1.160 |
Why?
|
| Potassium Channels, Tandem Pore Domain | 3 | 2019 | 34 | 1.110 |
Why?
|
| Vasoconstriction | 4 | 2020 | 92 | 0.800 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 2023 | 9 | 0.790 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2025 | 177 | 0.740 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2021 | 541 | 0.520 |
Why?
|
| Patient Admission | 1 | 2017 | 181 | 0.490 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 4 | 2019 | 622 | 0.450 |
Why?
|
| Neuromyelitis Optica | 1 | 2015 | 32 | 0.440 |
Why?
|
| rho-Associated Kinases | 1 | 2014 | 47 | 0.430 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2017 | 220 | 0.420 |
Why?
|
| Veterans | 2 | 2023 | 1741 | 0.410 |
Why?
|
| Antibodies, Neutralizing | 3 | 2021 | 496 | 0.410 |
Why?
|
| Nitric Oxide Synthase Type II | 3 | 2009 | 89 | 0.390 |
Why?
|
| Heart Diseases | 1 | 2017 | 490 | 0.380 |
Why?
|
| Inclusion Bodies | 2 | 2009 | 35 | 0.370 |
Why?
|
| DNA | 1 | 2014 | 1419 | 0.300 |
Why?
|
| Ventricular Function, Right | 3 | 2025 | 126 | 0.300 |
Why?
|
| Autophagy | 1 | 2011 | 404 | 0.270 |
Why?
|
| Adenosine Monophosphate | 3 | 2023 | 47 | 0.270 |
Why?
|
| Lung Diseases | 1 | 2011 | 395 | 0.260 |
Why?
|
| Alanine | 3 | 2023 | 162 | 0.260 |
Why?
|
| Stress, Physiological | 1 | 2009 | 257 | 0.250 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 2304 | 0.250 |
Why?
|
| Antiviral Agents | 2 | 2021 | 757 | 0.240 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-1 | 1 | 2025 | 32 | 0.230 |
Why?
|
| Male | 16 | 2025 | 62543 | 0.210 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2025 | 226 | 0.210 |
Why?
|
| Double-Blind Method | 3 | 2021 | 1584 | 0.210 |
Why?
|
| Cells, Cultured | 3 | 2025 | 2893 | 0.190 |
Why?
|
| Aged | 7 | 2023 | 20344 | 0.190 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2025 | 576 | 0.180 |
Why?
|
| Phenylephrine | 2 | 2019 | 34 | 0.170 |
Why?
|
| Peritoneal Dialysis | 1 | 2023 | 129 | 0.170 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2020 | 38 | 0.170 |
Why?
|
| Vascular Remodeling | 4 | 2025 | 46 | 0.170 |
Why?
|
| Pulmonary Fibrosis | 2 | 2019 | 111 | 0.170 |
Why?
|
| Hydra | 1 | 2020 | 3 | 0.160 |
Why?
|
| Aorta, Thoracic | 2 | 2017 | 535 | 0.160 |
Why?
|
| Endothelium | 1 | 2020 | 63 | 0.160 |
Why?
|
| Acute Lung Injury | 1 | 2020 | 64 | 0.160 |
Why?
|
| Extracellular Vesicles | 1 | 2020 | 54 | 0.150 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 1 | 2019 | 30 | 0.150 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2014 | 350 | 0.150 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 374 | 0.140 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2020 | 134 | 0.140 |
Why?
|
| Mice | 8 | 2025 | 17596 | 0.140 |
Why?
|
| Humans | 19 | 2025 | 126754 | 0.140 |
Why?
|
| Vasoconstrictor Agents | 1 | 2019 | 131 | 0.140 |
Why?
|
| Mice, Inbred C57BL | 4 | 2025 | 4504 | 0.140 |
Why?
|
| Female | 11 | 2023 | 68330 | 0.140 |
Why?
|
| Disease Progression | 3 | 2020 | 2109 | 0.130 |
Why?
|
| Adult | 8 | 2023 | 30410 | 0.130 |
Why?
|
| Mice, Knockout | 4 | 2025 | 3709 | 0.130 |
Why?
|
| Cytokines | 2 | 2015 | 1320 | 0.130 |
Why?
|
| Animals | 10 | 2025 | 33051 | 0.120 |
Why?
|
| Survival Rate | 2 | 2020 | 2101 | 0.120 |
Why?
|
| Longitudinal Studies | 2 | 2017 | 1428 | 0.120 |
Why?
|
| Action Potentials | 1 | 2019 | 463 | 0.120 |
Why?
|
| Disease Models, Animal | 5 | 2025 | 4429 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 988 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 361 | 0.120 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 1 | 2020 | 422 | 0.110 |
Why?
|
| Adenosine | 1 | 2016 | 126 | 0.110 |
Why?
|
| Emphysema | 1 | 2015 | 62 | 0.110 |
Why?
|
| Middle Aged | 6 | 2021 | 27697 | 0.110 |
Why?
|
| Echocardiography | 2 | 2019 | 1114 | 0.110 |
Why?
|
| Hypoxia | 1 | 2016 | 243 | 0.110 |
Why?
|
| Heart Atria | 1 | 2017 | 326 | 0.110 |
Why?
|
| Heart Ventricles | 1 | 2019 | 761 | 0.110 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2014 | 11 | 0.110 |
Why?
|
| Calcium | 1 | 2019 | 1031 | 0.100 |
Why?
|
| Protein Transport | 3 | 2009 | 349 | 0.100 |
Why?
|
| Cohort Studies | 1 | 2023 | 4954 | 0.100 |
Why?
|
| Pneumonia | 2 | 2014 | 334 | 0.100 |
Why?
|
| Vasodilation | 1 | 2013 | 173 | 0.090 |
Why?
|
| Comorbidity | 1 | 2017 | 1559 | 0.090 |
Why?
|
| Retrospective Studies | 2 | 2023 | 17005 | 0.090 |
Why?
|
| Enzyme Activation | 2 | 2009 | 577 | 0.090 |
Why?
|
| Intention to Treat Analysis | 2 | 2020 | 61 | 0.080 |
Why?
|
| Smoking | 1 | 2015 | 901 | 0.080 |
Why?
|
| Prevalence | 1 | 2017 | 2591 | 0.080 |
Why?
|
| Endothelium, Vascular | 1 | 2013 | 459 | 0.080 |
Why?
|
| Treatment Failure | 2 | 2021 | 334 | 0.080 |
Why?
|
| Incidence | 1 | 2017 | 3251 | 0.080 |
Why?
|
| src-Family Kinases | 1 | 2009 | 90 | 0.080 |
Why?
|
| Rhodamines | 1 | 2009 | 22 | 0.070 |
Why?
|
| Blood Pressure | 1 | 2014 | 1312 | 0.070 |
Why?
|
| Subcellular Fractions | 1 | 2009 | 87 | 0.070 |
Why?
|
| Genotype | 1 | 2014 | 2595 | 0.070 |
Why?
|
| Bronchi | 1 | 2009 | 102 | 0.070 |
Why?
|
| Signal Transduction | 2 | 2025 | 4472 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2021 | 1137 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2015 | 1705 | 0.060 |
Why?
|
| Cell Survival | 1 | 2009 | 841 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2021 | 12546 | 0.060 |
Why?
|
| Nitric Oxide | 1 | 2009 | 461 | 0.060 |
Why?
|
| Lung | 3 | 2020 | 1516 | 0.060 |
Why?
|
| Arterial Pressure | 1 | 2025 | 125 | 0.060 |
Why?
|
| Epithelial Cells | 1 | 2009 | 870 | 0.050 |
Why?
|
| Adolescent | 1 | 2021 | 20002 | 0.050 |
Why?
|
| Nucleocapsid | 1 | 2022 | 6 | 0.050 |
Why?
|
| Adaptive Clinical Trials as Topic | 1 | 2022 | 5 | 0.050 |
Why?
|
| Hospitalization | 2 | 2020 | 1874 | 0.050 |
Why?
|
| United States | 1 | 2017 | 11310 | 0.050 |
Why?
|
| Medical Futility | 1 | 2021 | 38 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2025 | 677 | 0.040 |
Why?
|
| Kallikrein-Kinin System | 1 | 2020 | 2 | 0.040 |
Why?
|
| Phenyl Ethers | 1 | 2020 | 7 | 0.040 |
Why?
|
| Scavenger Receptors, Class E | 1 | 2020 | 8 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 3662 | 0.040 |
Why?
|
| Clathrin | 1 | 2020 | 22 | 0.040 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2014 | 234 | 0.040 |
Why?
|
| Endothelin-1 | 1 | 2020 | 40 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 2021 | 389 | 0.040 |
Why?
|
| Renin-Angiotensin System | 1 | 2020 | 98 | 0.040 |
Why?
|
| Endocytosis | 1 | 2020 | 120 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2021 | 510 | 0.040 |
Why?
|
| Cell Death | 1 | 2020 | 236 | 0.040 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2019 | 10 | 0.040 |
Why?
|
| Fluorescent Dyes | 1 | 2020 | 245 | 0.040 |
Why?
|
| Bleomycin | 1 | 2019 | 110 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2020 | 330 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2025 | 2397 | 0.040 |
Why?
|
| Ventricular Remodeling | 1 | 2019 | 150 | 0.040 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2019 | 77 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2020 | 438 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 489 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2020 | 493 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2020 | 1126 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 283 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2020 | 501 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2025 | 2337 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2016 | 89 | 0.030 |
Why?
|
| Models, Animal | 1 | 2017 | 452 | 0.030 |
Why?
|
| Neoplasms | 1 | 2009 | 2855 | 0.030 |
Why?
|
| Exercise Test | 1 | 2015 | 243 | 0.030 |
Why?
|
| Interleukin-4 Receptor alpha Subunit | 1 | 2014 | 13 | 0.030 |
Why?
|
| STAT6 Transcription Factor | 1 | 2014 | 29 | 0.030 |
Why?
|
| Macrophage Activation | 1 | 2014 | 64 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2015 | 950 | 0.030 |
Why?
|
| Calcimycin | 1 | 2013 | 19 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2014 | 187 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2014 | 291 | 0.030 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2013 | 57 | 0.030 |
Why?
|
| Ubiquitin | 1 | 2014 | 130 | 0.020 |
Why?
|
| Indomethacin | 1 | 2013 | 81 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1135 | 0.020 |
Why?
|
| Biomarkers | 1 | 2021 | 3222 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2014 | 646 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2014 | 422 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2014 | 754 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 523 | 0.020 |
Why?
|
| Phosphoserine | 1 | 2009 | 36 | 0.020 |
Why?
|
| Enzyme Stability | 1 | 2009 | 56 | 0.020 |
Why?
|
| Half-Life | 1 | 2009 | 151 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2009 | 111 | 0.020 |
Why?
|
| Detergents | 1 | 2008 | 21 | 0.020 |
Why?
|
| Histone Deacetylase 6 | 1 | 2008 | 8 | 0.020 |
Why?
|
| Dyneins | 1 | 2008 | 12 | 0.020 |
Why?
|
| Epithelium | 1 | 2009 | 336 | 0.020 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2008 | 46 | 0.020 |
Why?
|
| Child | 2 | 2023 | 25101 | 0.020 |
Why?
|
| Cytosol | 1 | 2008 | 138 | 0.020 |
Why?
|
| Microtubules | 1 | 2008 | 118 | 0.020 |
Why?
|
| Histone Deacetylases | 1 | 2008 | 113 | 0.020 |
Why?
|
| Ubiquitination | 1 | 2008 | 168 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2008 | 372 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 2975 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2008 | 718 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2008 | 348 | 0.020 |
Why?
|
| Asthma | 1 | 2014 | 764 | 0.020 |
Why?
|
| Prognosis | 1 | 2015 | 4772 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2009 | 1536 | 0.020 |
Why?
|
| Heart Failure | 1 | 2019 | 2289 | 0.010 |
Why?
|
| Hypertension | 1 | 2013 | 1301 | 0.010 |
Why?
|
| Models, Biological | 1 | 2009 | 1370 | 0.010 |
Why?
|
| Protein Binding | 1 | 2008 | 1661 | 0.010 |
Why?
|
| Cell Line | 1 | 2008 | 2560 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2009 | 3498 | 0.010 |
Why?
|
| Phenotype | 1 | 2008 | 4304 | 0.010 |
Why?
|